Skip to main content
. 2021 Jul 20;11:687564. doi: 10.3389/fonc.2021.687564

Figure 2.

Figure 2

The survival analysis of the 20 patients with rGBM who received anlotinib and TMZ treatment. [(A) progression-free survival of IDH1+ group, IDH1−group, and the whole cohort; (B) overall survival of IDH1+ group, IDH1 –group, and the whole cohort; (C) progression-free survival of MGMT meth group, MGMT unmeth group, and the whole cohort; (D) overall survival of MGMT meth group, MGMT unmeth group, and the whole cohort].